Kazia Therapeutics (KZIA) Receivables (2017 - 2025)

Kazia Therapeutics' Receivables history spans 6 years, with the latest figure at $120401.4 for Q2 2025.

  • For Q2 2025, Receivables fell 95.31% year-over-year to $120401.4; the TTM value through Jun 2025 reached $120401.4, down 95.31%, while the annual FY2025 figure was $120401.4, 95.31% down from the prior year.
  • Receivables reached $120401.4 in Q2 2025 per KZIA's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.7 million in Q2 2023 to a low of $93831.1 in Q2 2022.
  • Average Receivables over 4 years is $1.4 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Receivables: skyrocketed 2751.34% in 2023, then plummeted 95.31% in 2025.
  • A 4-year view of Receivables shows it stood at $93831.1 in 2022, then surged by 2751.34% to $2.7 million in 2023, then fell by 4.01% to $2.6 million in 2024, then tumbled by 95.31% to $120401.4 in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Receivables are $120401.4 (Q2 2025), $2.6 million (Q2 2024), and $2.7 million (Q2 2023).